MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

MDT

99.8

-0.46%↓

147.83

+0.18%↑

VEEV

238.66

+0.24%↑

HQY

97.62

+2.79%↑

PHR.US

17.5

+1.74%↑

Начало・Списък с акции・Anavex Life Sciences Corp

Anavex Life Sciences Corp

Отворен

СекторЗдравеопазване

4.07 2.01

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.93

Максимум

4.19

Ключови измерители
By Trading Economics
Приходи	3.4M -9.8M
Служители	34
EBITDA	-2.1M -13M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+398.75% upside

Дивиденти
By Dow Jones
Следващи печалби	11.02.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	88M 353M
Предишно отваряне	2.06
Предишно затваряне	4.07

Настроения в новините

By Acuity

38%

62%

127 / 373 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Very Strong Bearish Evidence

8.275 / 9.312 Подкрепа & съпротива

Anavex Life Sciences Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

6.01.2026 г., 21:14 ч. UTC

Значими двигатели на пазара

Ventyx Biosciences Gains on Report of Possible $1 Billion Eli Lilly Deal

6.01.2026 г., 19:23 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4 Billion Hg Acquisition

6.01.2026 г., 17:41 ч. UTC

Значими двигатели на пазара

Blink Charging Shares Rise as EV Chargers Begin Accepting Cryptocurrency

6.01.2026 г., 15:46 ч. UTC

Придобивния, сливания и поглъщания

Advent International Leads InPost Takeover Offer, Sky News Says

6.01.2026 г., 15:37 ч. UTC

Значими двигатели на пазара

Terrestrial Energy Shares Rise After DOE Agreement For Nuclear Plant Development

6.01.2026 г., 23:46 ч. UTC

Пазарно говорене

Nikkei May Decline After Hitting Record High -- Market Talk

6.01.2026 г., 23:35 ч. UTC

Пазарно говорене

Gold Edges Higher Amid Ongoing Geopolitical Tensions -- Market Talk

6.01.2026 г., 23:19 ч. UTC

Пазарно говорене

Greatland 2Q Gold Output Strong, Sales Soft -- Market Talk

6.01.2026 г., 22:53 ч. UTC

Пазарно говорене

WiseTech, REA and CAR Look Best Insulated From AI Threat -- Market Talk

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical: Merger Proposal Received 14.9M Votes For and 27.3M Against

6.01.2026 г., 22:03 ч. UTC

Придобивния, сливания и поглъщания

Staar Surgical, Which Earlier Reported Stockholder Rejection of Sale to Alcon, Reports Vote Totals

6.01.2026 г., 21:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

6.01.2026 г., 21:15 ч. UTC

Пазарно говорене

Global Commodities Roundup: Market Talk

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Market Talk Roundup: Latest on U.S. Politics

6.01.2026 г., 21:12 ч. UTC

Пазарно говорене

Commodity Demand Helps Canada Reduce Reliance on Trade With U.S. -- Market Talk

6.01.2026 г., 20:59 ч. UTC

Значими двигатели на пазара

Придобивния, сливания и поглъщания

Ventyx Biosciences Gains on Report of Possible $1B Eli Lilly Deal

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Acquisition of Ventyx Would Bring Lilly Into Emerging Category of Pills for Inflammation-Related Conditions -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly Nears Deal for Biotech Ventyx -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Deal Could Be Announced Imminently, Sources Say -- WSJ

6.01.2026 г., 20:40 ч. UTC

Придобивния, сливания и поглъщания

Eli Lilly in Advanced Talks to Buy Ventyx Biosciences For Over $1B, Sources Say -- WSJ

6.01.2026 г., 20:01 ч. UTC

Пазарно говорене

Oil Futures Give Back Post-Venezuela Incursion Gains -- Market Talk

6.01.2026 г., 19:52 ч. UTC

Пазарно говорене

U.S. Natural Gas Falls Awaiting Colder Weather -- Market Talk

6.01.2026 г., 19:46 ч. UTC

Придобивния, сливания и поглъщания

Under Armour Stock Rises After the 'Warren Buffet of Canada' Boosts Its Stake -- Barrons.com

6.01.2026 г., 19:08 ч. UTC

Придобивния, сливания и поглъщания

OneStream to Go Private Through $6.4B Hg Acquisition

6.01.2026 г., 18:28 ч. UTC

Придобивния, сливания и поглъщания

These Stocks Are Moving the Most Today: Sandisk, Nvidia, AMD, Palantir, OneStream, SoFi, Microchip, and More -- Barrons.com

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Печалби

Financial Services Roundup: Market Talk

6.01.2026 г., 17:20 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Health Care Roundup: Market Talk

6.01.2026 г., 15:57 ч. UTC

Пазарно говорене

Crude Futures Ease Back From Early Gains -- Market Talk

6.01.2026 г., 15:34 ч. UTC

Пазарно говорене

Печалби

Bank of Montreal Expects to Exit 2027 With ROE Hitting 15% Target -- Market Talk

6.01.2026 г., 15:27 ч. UTC

Пазарно говорене

German Inflation Won't Fall Much Further in 2026 -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Anavex Life Sciences Corp Прогноза

Ценова цел

By TipRanks

398.75% нагоре

12-месечна прогноза

Среден 20 USD 398.75%

Висок 20 USD

Нисък 20 USD

Според 2 анализатори от Wall Street, предложили 12-месечна ценова цел за Anavex Life Sciences Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

2 ratings

Купи

Задържане

Продай

Според 2 анализатори, дали борсови рейтинги на Anavex Life Sciences Corp през последните 3 месеца.

Техническа оценка

By Trading Central

8.275 / 9.312Подкрепа & съпротива

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

The bullish and bearish events are balanced.

Настроение

By Acuity

127 / 373 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Anavex Life Sciences Corp

Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome. The company's drug candidate also comprises ANAVEX 3-71, which is in clinical trial for the treatment of schizophrenia, frontotemporal dementia, and Alzheimer's disease. Its preclinical drug candidates include ANAVEX 1-41 for the treatment of depression, stroke, and neurogenerative disease; ANAVEX 1066 for the potential treatment of neuropathic and visceral pain; and ANAVEX 1037 to treat prostate and pancreatic cancer. The company was incorporated in 2004 and is headquartered in New York, New York.